Cargando…

The Structural and Immunological Properties of Chimeric Proteins Containing HIV-1 MPER Sites

The human immunodeficiency virus (HIV-1) poses a serious risk to global public health. The development of a safe and effective vaccine could stop the HIV/AIDS pandemic. Much of the research focused on HIV-1 prevention through vaccination is aimed at developing immunogens and immunization strategies...

Descripción completa

Detalles Bibliográficos
Autores principales: Rudometov, A. P., Rudometova, N. B., Shcherbakov, D. N., Lomzov, A. A., Kaplina, O. N., Shcherbakova, N. S., Ilyichev, A. A., Bakulina, A. Yu., Karpenko, L. I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: A.I. Gordeyev 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826149/
https://www.ncbi.nlm.nih.gov/pubmed/31720017
http://dx.doi.org/10.32607/20758251-2019-11-3-56-65
_version_ 1783465025275428864
author Rudometov, A. P.
Rudometova, N. B.
Shcherbakov, D. N.
Lomzov, A. A.
Kaplina, O. N.
Shcherbakova, N. S.
Ilyichev, A. A.
Bakulina, A. Yu.
Karpenko, L. I.
author_facet Rudometov, A. P.
Rudometova, N. B.
Shcherbakov, D. N.
Lomzov, A. A.
Kaplina, O. N.
Shcherbakova, N. S.
Ilyichev, A. A.
Bakulina, A. Yu.
Karpenko, L. I.
author_sort Rudometov, A. P.
collection PubMed
description The human immunodeficiency virus (HIV-1) poses a serious risk to global public health. The development of a safe and effective vaccine could stop the HIV/AIDS pandemic. Much of the research focused on HIV-1 prevention through vaccination is aimed at developing immunogens and immunization strategies to induce the formation of antibodies with neutralizing activity against a broad range of HIV-1 isolates (bNAbs). The objective of this study was to develop immunogens capable of targeting an immune response to MPER, one of the regions of bNAb binding in Env. Two immunogens carrying MPER fragments on their scaffolds (protein YkuJ Bacillus subtilis and artificial polypeptide TBI) were constructed. Circular dichroism spectroscopy was used to show that the secondary structure of the immunogens was consistent with their theoretical models. The antigenic structure of the MPER-TBI and YkuJ-MPER proteins was characterized using bNAbs that recognize HIV-1 MPER (2F5, 4E10, and 10E8). The rabbit model made it possible to show the immunogenicity of the constructed recombinant proteins. The resulting serum was found to be cross-reactive with immunogens carrying MPER. The constructs designed and characterized in this study can be used for targeting the humoral immune response to MPER, which is known to be one of the sites of HIV-1 vulnerability.
format Online
Article
Text
id pubmed-6826149
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher A.I. Gordeyev
record_format MEDLINE/PubMed
spelling pubmed-68261492019-11-12 The Structural and Immunological Properties of Chimeric Proteins Containing HIV-1 MPER Sites Rudometov, A. P. Rudometova, N. B. Shcherbakov, D. N. Lomzov, A. A. Kaplina, O. N. Shcherbakova, N. S. Ilyichev, A. A. Bakulina, A. Yu. Karpenko, L. I. Acta Naturae Research Article The human immunodeficiency virus (HIV-1) poses a serious risk to global public health. The development of a safe and effective vaccine could stop the HIV/AIDS pandemic. Much of the research focused on HIV-1 prevention through vaccination is aimed at developing immunogens and immunization strategies to induce the formation of antibodies with neutralizing activity against a broad range of HIV-1 isolates (bNAbs). The objective of this study was to develop immunogens capable of targeting an immune response to MPER, one of the regions of bNAb binding in Env. Two immunogens carrying MPER fragments on their scaffolds (protein YkuJ Bacillus subtilis and artificial polypeptide TBI) were constructed. Circular dichroism spectroscopy was used to show that the secondary structure of the immunogens was consistent with their theoretical models. The antigenic structure of the MPER-TBI and YkuJ-MPER proteins was characterized using bNAbs that recognize HIV-1 MPER (2F5, 4E10, and 10E8). The rabbit model made it possible to show the immunogenicity of the constructed recombinant proteins. The resulting serum was found to be cross-reactive with immunogens carrying MPER. The constructs designed and characterized in this study can be used for targeting the humoral immune response to MPER, which is known to be one of the sites of HIV-1 vulnerability. A.I. Gordeyev 2019 /pmc/articles/PMC6826149/ /pubmed/31720017 http://dx.doi.org/10.32607/20758251-2019-11-3-56-65 Text en Copyright ® 2019 National Research University Higher School of Economics. http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Rudometov, A. P.
Rudometova, N. B.
Shcherbakov, D. N.
Lomzov, A. A.
Kaplina, O. N.
Shcherbakova, N. S.
Ilyichev, A. A.
Bakulina, A. Yu.
Karpenko, L. I.
The Structural and Immunological Properties of Chimeric Proteins Containing HIV-1 MPER Sites
title The Structural and Immunological Properties of Chimeric Proteins Containing HIV-1 MPER Sites
title_full The Structural and Immunological Properties of Chimeric Proteins Containing HIV-1 MPER Sites
title_fullStr The Structural and Immunological Properties of Chimeric Proteins Containing HIV-1 MPER Sites
title_full_unstemmed The Structural and Immunological Properties of Chimeric Proteins Containing HIV-1 MPER Sites
title_short The Structural and Immunological Properties of Chimeric Proteins Containing HIV-1 MPER Sites
title_sort structural and immunological properties of chimeric proteins containing hiv-1 mper sites
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826149/
https://www.ncbi.nlm.nih.gov/pubmed/31720017
http://dx.doi.org/10.32607/20758251-2019-11-3-56-65
work_keys_str_mv AT rudometovap thestructuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites
AT rudometovanb thestructuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites
AT shcherbakovdn thestructuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites
AT lomzovaa thestructuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites
AT kaplinaon thestructuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites
AT shcherbakovans thestructuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites
AT ilyichevaa thestructuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites
AT bakulinaayu thestructuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites
AT karpenkoli thestructuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites
AT rudometovap structuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites
AT rudometovanb structuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites
AT shcherbakovdn structuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites
AT lomzovaa structuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites
AT kaplinaon structuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites
AT shcherbakovans structuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites
AT ilyichevaa structuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites
AT bakulinaayu structuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites
AT karpenkoli structuralandimmunologicalpropertiesofchimericproteinscontaininghiv1mpersites